SELL and chronic myelogenous leukemia, BCR-ABL1 positive: CML patients under treatment with 2nd generation TKIs presented a significant increase in the density of CD62L on NKT-like cells when compared to CML patients treated with 1st generation TKI (MFI: 113 ± 42 vs. 170 ± 98; p = 0.0322) (Supplementary File 6).